Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03392337 · ClinicalTrials.gov registry record · NA
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
A NA study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03392337: Recruiting NA study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT03392337 is a NA study of Psoriasis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03392337, a NA study of Psoriasis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
Primary Outcome
PASI 75
Conditions Studied
Interventions
- DEVICE Narrowband UVB phototherapy
Study Locations (1)
New Jersey
- Elise Nelson - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2020-01-01 |
| Phase | NA |
What NCT03392337 shows while recruiting
NCT03392337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Narrowband UVB phototherapy is the first listed.
NCT03392337 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03392337 about?
NCT03392337 is a clinical study titled "An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients". A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
What is the current status of trial NCT03392337?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2017-11-07. Estimated completion is 2020-01-01.
What conditions does trial NCT03392337 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03392337?
The interventions under investigation include: Narrowband UVB phototherapy (DEVICE).
Who is sponsoring clinical trial NCT03392337?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03392337 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03392337's enrollment target sits among peer trials
30 95th of 125 higher than 26 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
RECRUITING · NA
-
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
RECRUITING · NA
-
Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
RECRUITING · NA
-
Deucravacitinib Adherence Study
ACTIVE NOT RECRUITING · NA
-
Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI